OssDsign AB
STO:OSSD
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6
10.88
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
OssDsign AB
Operating Income
OssDsign AB
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
OssDsign AB
STO:OSSD
|
Operating Income
-kr88.5m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Xvivo Perfusion AB
STO:XVIVO
|
Operating Income
kr56.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
46%
|
CAGR 10-Years
20%
|
|
|
D
|
Doxa AB
STO:DOXA
|
Operating Income
-kr7.5m
|
CAGR 3-Years
18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
10%
|
|
|
Bactiguard Holding AB
STO:BACTI B
|
Operating Income
-kr118m
|
CAGR 3-Years
-128%
|
CAGR 5-Years
-76%
|
CAGR 10-Years
N/A
|
|
|
V
|
Vimian Group AB
STO:VIMIAN
|
Operating Income
€39.4m
|
CAGR 3-Years
23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
S2Medical AB (publ)
STO:S2M
|
Operating Income
kr2.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
OssDsign AB
Glance View
OssDsign AB is a holding company, which designs, manufactures, and sells implants and material technology for bone regeneration. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2019-05-24. The company aims at developing implantable products that respond to clinical challenges, with focus on bone healing. Its primary focus is skull surgery. The firm uses design solutions, material compositions and manufacturing processes mainly based on proprietary bioceramic technologies. The bioceramics it uses integrate with tissues and support bone ingrowth. OssDsign AB's main product is Craniomosaic, an implant for the repair of skull defects (cranioplasty). Along with it, the Company develops bioceramic implants for facial bone augmentation. The firm's customers include neurosurgeons, craniofacial and maxillofacial surgeons.
See Also
What is OssDsign AB's Operating Income?
Operating Income
-88.5m
SEK
Based on the financial report for Dec 31, 2023, OssDsign AB's Operating Income amounts to -88.5m SEK.
What is OssDsign AB's Operating Income growth rate?
Operating Income CAGR 5Y
-12%
Over the last year, the Operating Income growth was 9%. The average annual Operating Income growth rates for OssDsign AB have been -2% over the past three years , -12% over the past five years .
You don't have any saved screeners yet
